2019
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology 2019, 127: p66-p145. PMID: 31757498, DOI: 10.1016/j.ophtha.2019.09.025.Peer-Reviewed Original ResearchPanretinal Photocoagulation along the Long Ciliary Nerve in Diabetic Retinopathy
Lu AJ, Freedman IG, Shakir O, Adelman RA, Del Priore LV. Panretinal Photocoagulation along the Long Ciliary Nerve in Diabetic Retinopathy. Ophthalmology Retina 2019, 3: 1105-1107. PMID: 31519540, DOI: 10.1016/j.oret.2019.07.002.Peer-Reviewed Original ResearchResponse to Vitrectomy in diabetic macular edema
Michalewska Z, Stewart MW, Landers MB, Bednarski M, Adelman RA, Nawrocki J. Response to Vitrectomy in diabetic macular edema. Canadian Journal Of Ophthalmology 2019, 54: 403-404. PMID: 31109488, DOI: 10.1016/j.jcjo.2019.04.007.Peer-Reviewed Original Research
2017
Vitrectomy in the management of diabetic macular edema in treatment-naïve patients
Michalewska Z, Stewart MW, Landers MB, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. Canadian Journal Of Ophthalmology 2017, 53: 402-407. PMID: 30119796, DOI: 10.1016/j.jcjo.2017.10.011.Peer-Reviewed Original ResearchConceptsTreatment-naïve diabetic macular edemaDiabetic macular edemaCentral retinal thicknessPars plana vitrectomyMacular edemaVisual acuityPlana vitrectomyMean central retinal thicknessDuration of diabetesProspective randomized trialsTreatment-naïve patientsInitial visual acuityVisual acuity changesPrimary outcome measureEfficacy of vitrectomyElectronic medical recordsEarly vitrectomyIntravitreal bevacizumabFinal BCVAMean BCVAPrimary endpointRetinal thicknessConsecutive patientsRandomized trialsRetrospective study
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 31: 342-345. PMID: 27813521, PMCID: PMC5306454, DOI: 10.1038/eye.2016.233.Peer-Reviewed Original ResearchAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent dataPredicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Strategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study
Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study. BioMed Research International 2015, 2015: 352487. PMID: 25695062, PMCID: PMC4324105, DOI: 10.1155/2015/352487.Peer-Reviewed Original ResearchMeSH KeywordsBasement MembraneDiabetic RetinopathyDisease ManagementHumansMacular EdemaRetinaVisual AcuityVitrectomyConceptsDiabetic macular edemaMacular edemaVisual acuityVisual improvementBetter visual improvementMulticenter clinical studyPars plana vitrectomySignificant visual improvementEdema studyTriamcinolone monotherapyVEGF therapyVEGF injectionVision gainClinical findingsGrid laserPlana vitrectomyRetina specialistsClinical studiesDifferent therapiesClinical informationEdemaAcuityTherapyMean numberTreatmentRecent developments in laser treatment of diabetic retinopathy
Yun SH, Adelman RA. Recent developments in laser treatment of diabetic retinopathy. Middle East African Journal Of Ophthalmology 2015, 22: 157-163. PMID: 25949072, PMCID: PMC4411611, DOI: 10.4103/0974-9233.150633.Peer-Reviewed Original ResearchConceptsDiabetic retinopathyAntivascular endothelial growth factor therapyEndothelial growth factor therapyProliferative diabetic retinopathyGrowth factor therapyPattern scan laserDiabetic retinopathy treatmentLaser treatmentFactor therapyMacular edemaLaser photocoagulationRetinopathy treatmentLaser therapyRetinopathyScan laserTherapyTreatmentEdemaPhotocoagulationMainstay
2007
Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis
Seth RK, Stoessel KM, Adelman RA. Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis. Seminars In Ophthalmology 2007, 22: 81-84. PMID: 17564926, DOI: 10.1080/08820530701418375.Peer-Reviewed Original ResearchConceptsWest Nile virus chorioretinitisChoroidal neovascularizationChoroidal Neovascularization AssociatedLate-onset complicationsBest therapeutic optionGood anatomical responseNeovascularization AssociatedDiabetes mellitusLeft eyeIntravitreal injectionTherapeutic optionsChorioretinitisNeovascularizationBevacizumabPatientsInjectionMellitusComplicationsBaseline
2003
WEST NILE VIRUS CHORIORETINITIS
ADELMAN RA, MEMBRENO JH, AFSHARI NA, STOESSEL KM. WEST NILE VIRUS CHORIORETINITIS. Retina 2003, 23: 100-101. PMID: 12652240, DOI: 10.1097/00006982-200302000-00017.Peer-Reviewed Original Research